Cluster of differentiation 3 consists of five different polypeptide chains with molecular weights ranging from 16 to 28 kD. CD3 have four different invariant chains: CD3 gamma, CD3 delta, CD3 epsilon, and CD3 zeta. The CD3 antigen is expressed in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T cell lineage.
In immunology, Cluster of differentiation 3 as T-cell co-receptor helps to activate the cytotoxic T-Cell. CD3 consists of a protein complex and is composed of four distinct chains. These chains associate with a molecule known as the T-cell receptor (TCR) and the ζ-chain (zeta-chain) to generate an activation signal in T lymphocytes. The TCR, ζ-chain, and CD3 molecules together constitute the TCR complex. The complex functions to transduce intracellular signals during TCR antigen recognition. CD3 epsilon is one of at least three invariant proteins that associate with the variable antigen recognition chains of the T cell receptor and function in signal transduction.
Cluster of differentiation 3 has high specificity, at all stages of T-cell development, makes it a useful immunohistochemical marker for T-cells in tissue sections. The antigen remains present in almost all T-cell lymphomas and leukaemias, and can therefore be used to distinguish them from superficially similar B-cell and myeloid neoplasms.
Because cluster of differentiation 3 is required for T-cell activation, drugs (often monoclonal antibodies) that target it are being investigated as immunosuppressant therapies for type 1 diabetes and other autoimmune diseases.
1. Hess C et al. HIV-1 specific CD8+ T-cells with an effector phenotype and control of viral replication. Lancet 363: 863-866, 2004
2. van Baarle et al. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 23 (12): 586-591, 2002
3. Boaz M et al. Presence of HIV-1 gag-specific IFN-gamma+ IL-2+ and CD28+ IL-2+ CD4 T cell responses is associated with non-progression in HIV-1 infection. J Immunol 169: 6376-6385, 2002
4. Shepard BD Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. J Acquir Immune Defic Syndr 48(2):149-155, 2008
5. Giorgi JV et al. Shorter survival in advanced HIV type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870, 1999
6. O'Brien TR et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14: 821-826, 2000
7. Leahy DJ, Axel R, Hendrickson WA. Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 A resolution. Cell 68 (6): 1145–62, 1992
8. Gao G, Jakobsen B. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today 21 (12): 630–6, 2000
9. CD8 alpha - Marker for cytotoxic T Lymphocytes. Retrieved 11 January 2016.